Draft:Moxaprindine

Moxaprindine
Clinical data
Other names	Moxaprindina, Moxaprindinum.
Identifiers
	IUPAC name N1-(2,3-Dihydro-1-methoxy-1H-inden-2-yl)-N3,N3-diethyl-N1-phenyl-1,3-propanediamine;
CAS Number	53076-26-9;
PubChem CID	68699;
ChemSpider	61950;
UNII	5HAF6QO904;
ChEMBL	ChEMBL2104713;
Chemical and physical data
Formula	C23H32N2O
Molar mass	352.522 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)CCCN(C1CC2=CC=CC=C2C1OC)C3=CC=CC=C3;
	InChI InChI=1S/C23H32N2O/c1-4-24(5-2)16-11-17-25(20-13-7-6-8-14-20)22-18-19-12-9-10-15-21(19)23(22)26-3/h6-10,12-15,22-23H,4-5,11,16-18H2,1-3H3; Key:QQGGXAOUSKREAE-UHFFFAOYSA-N;

Submission declined on 13 November 2025 by WeirdNAnnoyed (talk).

This does not appear to be a notable compound. All sources cited are primary as far as I can tell, and are badly out of date (the statement "Moxaprindine is a promising new antiarrhythmic drug" should absolutely not be sourced to a paper from 1981). Also the "pharmacology" section is unfinished: Either write in a properly-cited summary or eliminate the section. However, without secondary sources covering this topic I don't think this drug is worthy of a WP article. If secondary sources can be found, add them and resubmit.

This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:

in-depth (not just passing mentions about the subject)
reliable
secondary
independent of the subject

Make sure you add references that meet these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.

If you would like to continue working on the submission, click on the "Edit" tab at the top of the window.
If you have not resolved the issues listed above, your draft will be declined again and potentially deleted.
If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors.
Please do not remove reviewer comments or this notice until the submission is accepted.

Where to get help

If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews.
If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed.

How to improve a draft

Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia.
Help:Wikitext – how to use the markup
Help:Referencing for beginners – how to include references
Wikipedia:Article development – how to develop your article
Wikipedia:Writing better articles – how to improve your article
Wikipedia:Verifiability – make sure your article includes reliable third-party sources

You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article.

Improving your odds of a speedy review

To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags.

Add tags to your draft

Editor resources

Easy tools: Citation bot (help) | Advanced: Fix bare URLs

Declined by WeirdNAnnoyed 19 hours ago. Last edited by WeirdNAnnoyed 19 hours ago. Reviewer: Inform author.

Resubmit

Please note that if the issues are not fixed, the draft will be declined again.

Moxaprindine is a Class I antiarrhythmic agent that acts as a sodium channel blocker, used experimentally for treating ventricular and supraventricular arrhythmias. Its pharmacological profile resembles that of aprindine, with high protein binding and potent membrane-stabilizing effects.

Moxaprindine is a promising new antiarrhythmic drug for the treatment of ventricular arrhythmias, but its value and safely in the chronic oral treatment of these arrhythmias remain to be established.^[1]

Moxaprindine could be considered a clinically safer anti-arrhythmic agent than aprindine.^[2]

Pharmacology

The pharmacology is described:

Pharmacology:^[3]^[4]^[5]

Synthesis

The synthesis has been reported:^[6] Patent:^[7] Starting material:^[8] Recent article:^[9]

The reaction of 1-Methoxyindan-2-ol [71720-52-0] (1) with mesyl chloride gives 1-methoxy-2-mesyloxy-indane, PC11831595 (2). Displacement of the leaving group by aniline gives 1-methoxy-2-phenylamino-indane [53076-24-7] (3). Alkylation with 3-Chloropropyl(diethyl)amine [104-77-8] (4) in the presence of sodamide completed the synthesis of Moxaprindine (5).

References

^ Staessen, J., Kesteloot, H. (February 1981). "Moxaprindine in the acute treatment of ventricular arrhythmias in patients with cardiovascular disease". European Journal of Clinical Pharmacology. 19 (3): 167–172. doi:10.1007/BF00561943. PMID 7215413.
^ Stryckmans, P. A., Ronge‐Collard, E., Delforge, A., Lambert, M., Suciu, S. (October 1982). "Effect of 2 Anti-Arrhythmic Drugs Aprindine and Moxaprindine on the Replication Capacity of Murine and Human Haemopoietic Cells". Scandinavian Journal of Haematology. 29 (4): 331–337. doi:10.1111/j.1600-0609.1982.tb00603.x. PMID 7178839.
^ Teirlynck, O., Belpaire, F. M., Andreasen, F. (1982). "Binding of Aprindine and Moxaprindine to Human Serum, ?1-Acid Glycoprotien and Serum of Healthy and Diseased Humans". European Journal of Clinical Pharmacology. 22 (5): 472. doi:10.1007/BF00542556.
^ Teirlynck, O., Belpaire, F. M., Andreasen, F. (1982). "Binding of aprindine and moxaprindine to human serum, ?1-acid glycoprotein and serum of healthy and diseased humans". European Journal of Clinical Pharmacology. 21 (5): 427–431. doi:10.1007/BF00542331. PMID 7075647.
^ Kesteloot H, van de Werf F, Marchandise B, Sluyts R (1979). "Influence of moxaprindine treatment on ventricular arrhythmias occurring during maximal exercise stress testing". Acta Cardiologica. 34 (5): 301–9. PMID 317204.
^ Castañer, J., Thorpe, P. J. (1981). "Moxaprindine". Drugs of the Future. 6 (6): 354. doi:10.1358/dof.1981.006.06.1003862. ISSN 0377-8282. Retrieved 3 November 2025.
^ Pierre Vanhoof, Pierre Clarebout, DE2355039 (1974 to Manuf Prod Pharma).
^ Shigeru Nakano, Noriko Yoneta, & Takashi Tate, US6127579 (2000 to Ichikawa Gosei Chemical Co Ltd).
^ Horáková, E., Valtr, J., Dostálová, K., Drabina, P., Váňa, J., Růžička, A., Hanusek, J. (9 April 2019). "A Kinetic Study of the Intramolecular Nitroaldol (Henry) Reaction Giving 2-Nitroindan-1-ols". ChemistrySelect. 4 (13): 3973–3979. doi:10.1002/slct.201900481.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

This article about an amine is a stub. You can help Wikipedia by expanding it.

Category:2-Aminoindanes Category:Anilines Category:Antiarrhythmic agents Category:Sodium channel blockers Category:Diethylamino compounds

References

[1] Staessen, J., Kesteloot, H. (February 1981). "Moxaprindine in the acute treatment of ventricular arrhythmias in patients with cardiovascular disease". European Journal of Clinical Pharmacology. 19 (3): 167–172. doi:10.1007/BF00561943. PMID 7215413.

[2] Stryckmans, P. A., Ronge‐Collard, E., Delforge, A., Lambert, M., Suciu, S. (October 1982). "Effect of 2 Anti-Arrhythmic Drugs Aprindine and Moxaprindine on the Replication Capacity of Murine and Human Haemopoietic Cells". Scandinavian Journal of Haematology. 29 (4): 331–337. doi:10.1111/j.1600-0609.1982.tb00603.x. PMID 7178839.

[3] Teirlynck, O., Belpaire, F. M., Andreasen, F. (1982). "Binding of Aprindine and Moxaprindine to Human Serum, ?1-Acid Glycoprotien and Serum of Healthy and Diseased Humans". European Journal of Clinical Pharmacology. 22 (5): 472. doi:10.1007/BF00542556.

[4] Teirlynck, O., Belpaire, F. M., Andreasen, F. (1982). "Binding of aprindine and moxaprindine to human serum, ?1-acid glycoprotein and serum of healthy and diseased humans". European Journal of Clinical Pharmacology. 21 (5): 427–431. doi:10.1007/BF00542331. PMID 7075647.

[pmid317204-5] Kesteloot H, van de Werf F, Marchandise B, Sluyts R (1979). "Influence of moxaprindine treatment on ventricular arrhythmias occurring during maximal exercise stress testing". Acta Cardiologica. 34 (5): 301–9. PMID 317204.

[6] Castañer, J., Thorpe, P. J. (1981). "Moxaprindine". Drugs of the Future. 6 (6): 354. doi:10.1358/dof.1981.006.06.1003862. ISSN 0377-8282. Retrieved 3 November 2025.

[7] Pierre Vanhoof, Pierre Clarebout, DE2355039 (1974 to Manuf Prod Pharma).

[8] Shigeru Nakano, Noriko Yoneta, & Takashi Tate, US6127579 (2000 to Ichikawa Gosei Chemical Co Ltd).

[9] Horáková, E., Valtr, J., Dostálová, K., Drabina, P., Váňa, J., Růžička, A., Hanusek, J. (9 April 2019). "A Kinetic Study of the Intramolecular Nitroaldol (Henry) Reaction Giving 2-Nitroindan-1-ols". ChemistrySelect. 4 (13): 3973–3979. doi:10.1002/slct.201900481.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]